5/16
08:15 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "neutral" rating on the stock.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "neutral" rating on the stock.
5/13
10:56 am
fate
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/11
08:49 am
fate
Fate Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]
Low
Report
Fate Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]
5/11
12:15 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
5/10
03:43 pm
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $11.00 to $9.00. They now have a "buy" rating on the stock.
Low
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $11.00 to $9.00. They now have a "buy" rating on the stock.
5/10
11:23 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at BMO Capital Markets from $7.00 to $6.00. They now have a "market perform" rating on the stock.
Low
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at BMO Capital Markets from $7.00 to $6.00. They now have a "market perform" rating on the stock.
5/10
09:33 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Piper Sandler from $7.00 to $4.00. They now have a "neutral" rating on the stock.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Piper Sandler from $7.00 to $4.00. They now have a "neutral" rating on the stock.
5/9
04:12 pm
fate
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]
Low
Report
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]
5/9
04:01 pm
fate
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Medium
Report
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
5/9
08:30 am
fate
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
Medium
Report
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
5/6
08:40 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
Low
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
5/6
08:13 am
fate
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates [Yahoo! Finance]
Low
Report
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates [Yahoo! Finance]
5/6
08:00 am
fate
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
Low
Report
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
5/3
04:30 pm
fate
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
Low
Report
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
4/29
12:25 pm
fate
Fate Therapeutics: Looking For A Potential Turnaround In 2024 [Seeking Alpha]
Low
Report
Fate Therapeutics: Looking For A Potential Turnaround In 2024 [Seeking Alpha]
4/23
01:33 pm
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
Low
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
4/22
04:34 pm
fate
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting [Yahoo! Finance]
Medium
Report
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting [Yahoo! Finance]
4/22
04:30 pm
fate
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Medium
Report
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
4/11
08:06 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
4/6
04:00 am
fate
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress [Yahoo! Finance]
Medium
Report
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress [Yahoo! Finance]
4/3
08:24 am
fate
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Low
Report
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/3
08:00 am
fate
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
4/2
04:01 pm
fate
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
3/27
01:29 pm
fate
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Low
Report
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
3/19
08:56 am
fate
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement [Yahoo! Finance]
Low
Report
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement [Yahoo! Finance]